Treatment of Normal Pressure Hydrocephalus (NPH)

Treatment of Normal Pressure Hydrocephalus (NPH)

Overview

Treatment of Normal Pressure Hydrocephalus (NPH)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatment of Normal Pressure Hydrocephalus (NPH)</th>
</tr>
<tr>
<td class="label">Symptom</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Gait disturbance</td>
<td>Magnetic gait, difficulty initiating steps</td>
</tr>
<tr>
<td class="label">Cognitive impairment</td>
<td>Frontal executive dysfunction, apathy</td>
</tr>
<tr>
<td class="label">Urinary incontinence</td>
<td>Urgency, frequency, sometimes complete loss</td>
</tr>
<tr>
<td class="label">Shunt Type</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Programmable valve</td>
<td>Adjustable pressure non-invasively</td>
</tr>
<tr>
<td class="label">Fixed pressure</td>
<td>Simpler, less expensive</td>
</tr>
<tr>
<td class="label">Anti-siphon device</td>
<td>Reduces overdrainage</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Key Distinguishing Features</td>
</tr>
<tr>
<td class="label">Alzheimer disease</td>
<td>Memory loss prominent, no gait improvement post-tap</td>
</tr>
<tr>
<td class="label">Parkinson disease</td>
<td>Tremor, rigidity, no ventriculomegaly</td>
</tr>
<tr>
<td class="label">Vascular dementia</td>
<td>Stepwise progression, MRI evidence of strokes</td>
</tr>
<tr>
<td class="label">Frontotemporal dementia</td>
<td>Behavioral changes, early personality changes</td>
</tr>
</table>

Normal Pressure Hydrocephalus (NPH) is a treatable cause of dementia, gait disturbance, and urinary incontinence in older adults. Unlike other neurodegenerative conditions, NPH often responds well to surgical intervention, making accurate diagnosis crucial["@relkin2005"].

Epidemiology

• Prevalence: Estimated 0.5-3% of individuals over 65 years old[@kiefer2012]
• Age: Typically presents in adults aged 60-80 years
• Risk factors: Advanced age, history of traumatic brain injury, subarachnoid hemorrhage, or meningitis

Pathophysiology

NPH is characterized by:

Clinical Presentation

Cardinal Triad

Gait Abnormalities

• Broad-based, shuffling gait
• Difficulty with turns (turning en bloc)
• Frequent falls
• "Magnetic" feet - difficulty lifting feet off floor

Cognitive Profile

• Executive dysfunction (planning, problem-solving)
• Slowed processing speed
• Apathy and decreased motivation
• Memory relatively preserved early

Diagnostic Workup

Clinical Assessment

Imaging

• MRI brain: Ventricular enlargement (Evans index >0.3), periventricular hyperintensities, callosal angle <90° on T2 sequences[@ishikawa2008]
• CT brain: Can identify ventricular enlargement, helpful in ruling out other causes

CSF Tap Test

• Remove 30-50 mL of CSF via lumbar puncture
• Evaluate gait and cognitive function 1-2 hours post-tap
• Positive response: Significant improvement in gait or cognition (sensitivity 50-80%, specificity 70-90%)

External CSF Drainage

• 24-72 hour continuous CSF drainage via lumbar drain
• More sensitive than tap test (80-90% sensitivity)
• Used when tap test is equivocal

Treatment Approaches

Surgical Intervention

Ventriculoperitoneal (VP) Shunt

First-line treatment for clinically suspected NPH[@mori2012]:

Outcomes:

• 60-80% of patients show improvement
• Gait improves first (weeks to months)
• Cognitive improvement may take 3-6 months
• Long-term benefit in 50-70% of responders

Other Surgical Options

• Ventriculoatrial (VA) shunt: Alternative when VP not suitable
• Lumboperitoneal shunt: Less invasive, for selected patients
• Endoscopic third ventriculostomy: Rarely used for NPH

Medical Management

Acetazolamide

• Carbonic anhydrase inhibitor
• Reduces CSF production temporarily
• Limited evidence, mainly as bridge therapy
• Dose: 250-500 mg 2-3 times daily

Diuretics

• Furosemide may provide modest benefit
• Limited evidence base
• Monitor electrolytes

Supportive Management

Prognosis

With Treatment

• Shunt responders: 50-70% maintain improvement at 5 years
• Gait: Most responsive to treatment
• Cognition: Variable, may continue to decline despite shunt
• Urinary symptoms: Improve in majority, but may persist

Without Treatment

• Progressive decline over 1-3 years
• Increased fall risk
• Complete incontinence
• Severe cognitive impairment

Differential Diagnosis

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References